Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin alfa + urofollitropin
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
This entry refers to the comparative use of **follitropin alfa** (recombinant human follicle-stimulating hormone, rFSH) and **urofollitropin** (highly purified urinary follicle-stimulating hormone, HP-FSH) in controlled ovarian stimulation. Follitropin alfa is produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells, while urofollitropin is extracted and purified from the urine of postmenopausal women. Both agents act as agonists at the follicle-stimulating hormone receptor (FSHR), mimicking endogenous FSH to stimulate the recruitment and development of multiple ovarian follicles. This specific comparison was evaluated by the **Genesis Center for Fertility & Human Pre-Implantation Genetics** in patients with **polycystic ovary syndrome (PCOS)** undergoing in vitro fertilization (IVF) to assess differences in ovarian response, pregnancy rates, and miscarriage rates between the recombinant and urinary-derived formulations.
- Brand names
- Gonal-FFostimon
- Other names
- follitropin alfa + urofollitropin-Genesis Center for Fertility & Human Pre-Implantation Genetics-polycystic ovary syndromerecombinant human follicle stimulating hormone + highly purified follicle stimulating hormone
02
Targets
FSHR (Follicle-stimulating hormone receptor)
Beyond the preview
Go deeper on follitropin alfa + urofollitropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin alfa + urofollitropin.